Diabetes News and Research

Latest Diabetes News and Research

Geron collaborates to explore hESC-based product for Alzheimer’s disease

Geron Corporation today announced that it has entered into a collaboration jointly funded by Geron and a University of California Discovery Research and Training Grant to investigate the therapeutic potential of its human embryonic stem cell (hESC)-based product, GRNOPC1, for Alzheimer’s disease. The company is currently developing GRNOPC1 for the potential treatment of spinal cord injury.

27 Jan 2010

Potential risk factors in skipping insulin injections

More than half of people with diabetes who take insulin injections to control their diabetes say they have intentionally skipped an injection, with one-fifth of them reporting that they do so "sometimes" or "often," according to a study being published this month in Diabetes Care.

27 Jan 2010

Cinergy Health creates five steps to reduce childhood obesity

Cinergy Health, a nationwide health insurance agency providing guaranteed issue and short term major medical insurance programs, responds to the alarming rise in childhood obesity. One in three children in America is overweight or obese and one out of every five teenagers has a cholesterol level that increases the risk of heart disease.

27 Jan 2010

Burnham renamed to honor T. Denny Sanford's support

Burnham Institute for Medical Research (Burnham) announced today that philanthropist T. Denny Sanford has pledged $50 million to support and further expand and accelerate the Institute's leading-edge medical research. To honor Sanford, Burnham, has been renamed the Sanford-Burnham Medical Research Institute. This is the second gift Sanford has made to Burnham. In 2007, he directed $20 million through Sanford Health to create the Sanford Children's Health Research Center at Burnham.

27 Jan 2010

Health Canada approves first post-surgical treatment for patients with gastrointestinal stromal tumours

Patients with gastrointestinal stromal tumours (GIST) can now take action at an earlier stage of this rare form of cancer to reduce the risk of their disease returning following surgery. Novartis Pharmaceuticals Canada announced today that Gleevec* (imatinib mesylate) has received conditional approval by Health Canada for the adjuvant (post-surgical) treatment of adult patients who are at intermediate to high risk of disease recurrence following the surgical removal of GIST.

27 Jan 2010

EpiCept's NP-1 for treatment of PHN receives FDA orphan drug designation

EpiCept Corporation announced today that EpiCeptTM NP-1 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of post-herpetic neuralgia (PHN). NP-1 is a prescription topical analgesic cream designed to provide long-term relief from the pain of peripheral neuropathies.

27 Jan 2010

UCF researcher develops first dual vaccine to fight malaria and cholera

A University of Central Florida biomedical researcher has developed what promises to be the first low-cost dual vaccine against malaria and cholera.

27 Jan 2010

Osiris Therapeutics completes enrollment in Prochymal MSC therapy Phase II trial for type 1 diabetes

Osiris Therapeutics, Inc. today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell (MSC) therapy, as a treatment for patients recently diagnosed with type 1 diabetes. The milestone is the fourth in a series of payments resulting from JDRF’s partnership with Osiris for the development of a therapy for type 1 diabetes.

27 Jan 2010

Findings may point toward potential therapies for type 2 diabetes

In people who put on a lot of weight, or whose bodies start developing the inability to use insulin effectively that leads toward type 2 diabetes, the pancreas typically ramps up its supply of insulin-generating "beta" cells, at least partly by replication of the existing cells.

27 Jan 2010

Obese children face increased risk of stroke and heart disease

By as early as 7 years of age, being obese may raise a child's risk of future heart disease and stroke, even in the absence of other cardiovascular risk factors such as high blood pressure, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

27 Jan 2010

FDA approves Victoza to treat type 2 diabetes in some adults

The U.S. Food and Drug Administration today approved Victoza (liraglutide), a once-daily injection to treat type 2 diabetes in some adults.

27 Jan 2010

FDA approves Novo Nordisk's Victoza for type 2 diabetes

Novo Nordisk, a global healthcare company, announced today the U.S. Food and Drug Administration (FDA) approved the new drug application for Victoza® (liraglutide [rDNA origin] injection), the first once-daily human glucagon-like peptide-1 (GLP-1) analog for the treatment of type 2 diabetes. Victoza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.

27 Jan 2010

Number of Americans in excellent or good health has declined

The New York Times reports on health in the U.S. "The percentage of people who reported having excellent or very good health declined to 66.6 percent in the 2009 period, from 69.1 percent in 1998.

27 Jan 2010

Promising results in mice could prevent fatal iron buildup in humans

A new study shows that a protein found in blood alleviates anemia, a condition in which the body's tissues don't get enough oxygen from the blood. In this animal study, injections of the protein, known as transferrin, also protected against potentially fatal iron overload in mice with thalassemia, a type of inherited anemia that affects millions of people worldwide.

27 Jan 2010

IntegraGen now offers Fluidigm's IFC technology to French researchers

Fluidigm, the inventor of integrated fluidic circuits (IFCs), has joined with IntegraGen SA, one of France’s leading providers of genetic research testing services, to bring IFC technology to French researchers. IntegraGen will offer premium class services to its customers using the Fluidigm BioMark™ System for Genetic Analysis and the Access Array™ sample preparation system for next-generation sequencing. IntegraGen’s lab will also be a demonstration site for researchers investigating Fluidigm’s technology.

25 Jan 2010

AMT reaches another milestone in the official marketing authorisation process for Glybera

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, has reached another important milestone in the official marketing authorisation process for its lead product Glybera(R), AMT's proprietary product for lipoprotein lipase deficiency (LPLD).

25 Jan 2010

Renowned heart specialists to discuss new cardiovascular treatment and patient care at public forum

World-leading cardiovascular specialists, researchers, family physicians and the public will learn what's new in cardiovascular treatment, patient care and research at the second annual Peter Munk Cardiovascular Symposium, Partnerships in Integrative Patient Care, on January 29 and 30 at the Toronto Metropolitan Hotel.

23 Jan 2010

Study of 16INK4A gene's role in progression of retinoblastoma

Retinoblastoma is a pediatric eye cancer initiated by the loss or mutation of both copies of the retinoblastoma gene. Current evidence suggests that additional genetic alterations are required for retinoblastoma to become fully malignant.

23 Jan 2010

UK Gill Heart Institute offers individualized fitness program for heart patients

How do you change health habits among a population with some of the highest heart disease rates in the world? Tackling heart disease in Kentucky - an epicenter of heart health problems - the University of Kentucky Gill Heart Institute Cardiac Rehabilitation Program is helping high-risk patients make radical, lasting changes to improve their heart health.

23 Jan 2010

Lifestyle changes are best defense against heart attack

When it comes to heart health, whether or not your job is stressful isn't what you should be worried about, according to doctors at UT Southwestern Medical Center. Diet, exercise and risk factors like high cholesterol, smoking, diabetes, high blood pressure and obesity are what contribute to a person's chance of having a heart attack.

23 Jan 2010